Invest in Medtech
with Procope Medicals

The reason for Medtech

Investing in MedTech, a sector with exponential growth.

In France, heart failure affects 2.3% of the adult population and 10% of people over 70, i.e. more than 1 million French people.

The number of heart failure patients has almost doubled worldwide in the past 30 years, from 33.5 million in 1990 to 64.3 million in 2017.

There is an urgent need to invest in the development of medical solutions that allows patients to wait for a heart transplant.
Develop reliable and discreet technology
Meet the growing demand
Extend patient life expectancy

A global disease

Heart failure mainly affects those over the age of 30, all over the world.

At its most advanced stages, it affects around 160,000 patients and causes nearly 70,000 deaths in France per year.

All types of people can be affected by heart failure.

Growing needs

5,500 artificial hearts are transplanted every year, allowing patients to wait for a natural heart.

This represents only 3% of the transplants that are needed. 65% of patients with severe heart failure die within 12 months.

Therefore, the ongoing development of cardiac prosthetic solutions is essential.

Investing in MedTech

In 2021, French Medtech companies raised 2.3 billion euros and immediately created more than 10,000 jobs.

The global MedTech market is estimated to reach $600 billion by 2024, with earnings growing by 5-7% per year.

Procope Medicals, An Ambitious Startup

MedTech in France is a 28 billion euro market.

At Procope Medicals, we are aiming towards a 240 million euro turnover.

We’re now turning to the investors who’d like to support us and believe in the future of our medical and biotechnological solutions.
Discover the artificial heart developed by Procope Medicals - the first cardiac prosthesis that is completely implantable in a patient’s chest.
Find out more
Since 2018, our team has been working on the development of an innovative artificial heart that is less imposing than existing models and therefore more universal. Our ambition is to extend the life of all patients with severe heart failure until transplantation.

Let’s talk about it!

Let’s meet to discuss Procope Medicals, Medtech, our heart prosthesis, target dates and your goals.

Contact us

Our team is available to answer your questions about Procope Medicals or our cardiac prosthesis.

    Benefit from a 25% tax reduction under the IR-PME scheme !

    By taking advantage of this reduction, you can not only support innovation but also make substantial savings on your tax return.

    So go ahead, become a shareholder and contribute to the development of our cardiac prosthesis!

    Our Founders

    Saïd Chabane, Stéphanie Gouraud and Samuel Plumejault are joining forces Procope Medicals